Good News !! USA’s National Institute of Allergy and Infectious Diseases (NIAID) has done successful trial and found 100 percent efficiency of Dengue fever Vaccine
Dengue fever Vaccine TV003 is live attenuated vaccine which means the virus is weakened so that it does not lead to any effect on human system when injected but it stimulates immunologic memory that helps humans to counter the future viral infections.
TV003 vaccine uses dengue-2 serotype . Brazil’s Butantan Institute initiated TV003 vaccine into a large phase 3 efficacy trial. Phase III studies are randomized controlled multicenter trials on large patient groups (300–3,000 or more depending upon the disease/medical condition studied) and are aimed at being the definitive assessment of how effective the drug is, in comparison with current ‘gold standard’ treatment.
Dengvaxia, developed by the French pharmaceutical company Sanofi, has been approved for use in three countries: Mexico and the Philippines approved the vaccine earlier this month.